Disease characteristics and monitoring of IDH1/IDH2-mutated acute myeloid leukemia

Disease characteristics and monitoring of IDH1/IDH2-mutated acute myeloid leukemia

Saved in:

Bibliographic Details
Main Authors:	Mélinda Dantec, Maxime Dufossé, Augustin Boudry, Elise Fournier, Laure Goursaud, Delphine Lebon, Claire Bories, Isabelle Plantier, Sabine Tricot, Adrien Daniel, Alexandre Willaume, Valérie Coiteux, Céline Berthon, Jean-Pierre Marolleau, Claude Preudhomme, Nicolas Duployez, Laurène Fenwarth
Format:	Article
Language:	English
Published:	Nature Publishing Group 2025-05-01
Series:	Blood Cancer Journal
Online Access:	https://doi.org/10.1038/s41408-025-01304-x
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

NPM1 mutation subtype switch in acute myeloid leukemia
by: Benjamin Podvin, et al.
Published: (2025-03-01)

Screen for IDH1, IDH2, IDH3, D2HGDH and L2HGDH mutations in glioblastoma.
by: Daniel Krell, et al.
Published: (2011-01-01)

GENETIC BIOMARKERS OF GLIAL BRAIN TUMORS: IDH1 AND IDH2 MUTATIONS
by: M. Yu. Prokudin, et al.
Published: (2020-09-01)

Vorasidenib- A Paradigm Shift in IDH1- or IDH2-Mutant Low-Grade Glioma Treatment
by: Hurais Malik, et al.
Published: (2024-09-01)

IDH1(R132H) Immunoexpression in Glioma
by: Nyan Saeed Omer, et al.
Published: (2023-03-01)

Exploiting the therapeutic vulnerability of IDH-mutant gliomas with zotiraciclib
by: Ying Pang, et al.
Published: (2025-04-01)

Metabolic reprogramming in mutant IDH1 glioma cells.
by: Jose L Izquierdo-Garcia, et al.
Published: (2015-01-01)

IDH Mutant Cholangiocarcinoma: Pathogenesis, Management, and Future Therapies
by: Alexander Bray, et al.
Published: (2025-01-01)

Comparative Clinical-Imaging and Histogenetic Analysis Between Astrocytoma IDH-Mutant Grade 4 and Glioblastoma IDH-Wildtype—Is There Really a Worse One?
by: Cristian Ionut Orasanu, et al.
Published: (2025-02-01)

IDH Mutations in Glioma: Molecular, Cellular, Diagnostic, and Clinical Implications
by: Kristian A. Choate, et al.
Published: (2024-10-01)

Dissecting the Immunological Microenvironment of Glioma Based on IDH Status: Implications for Immunotherapy
by: Miyu Kikuchi, et al.
Published: (2025-07-01)

IDH mutant glioma: the role of 2HG in seizure production and tumorigenesis
by: Hiroaki Nagashima, et al.
Published: (2025-01-01)

IDH1 regulates human erythropoiesis by eliciting chromatin state reprogramming
by: Mengjia Li, et al.
Published: (2025-04-01)

Novel metabolic subtypes in IDH-mutant gliomas: implications for prognosis and therapy
by: Peng Wang, et al.
Published: (2025-04-01)

Scaffold modification and synthesis routes for targeting mutant IDH 1: a review
by: Vasavi S. Pai, et al.
Published: (2025-07-01)

Integration of MRI radiomics and germline genetics to predict the IDH mutation status of gliomas
by: Taishi Nakase, et al.
Published: (2025-06-01)

Vorasidenib for IDH-mutant grade 2 gliomas: clinical advances and future directions
by: Zhenjiang Pan, et al.
Published: (2025-06-01)

Spectrum of IDH-mutant tumors in Ollier-Maffucci disease: the triple interaction theory
by: Emmanuel Mandonnet, et al.
Published: (2024-11-01)

Valproic acid targets IDH1 mutants through alteration of lipid metabolism
by: Lubayna S. Elahi, et al.
Published: (2024-08-01)

Spinal IDH-wildtype glioma: a single center experience of rare disease
by: H. Gull, et al.
Published: (2024-01-01)

Proton therapy for adult type IDH-mutated glioma: Proglio-1, a multicenter retrospective study
by: Nicolas Goliot, et al.
Published: (2025-08-01)

Metabolic profiling in TET2 and IDH2 mutant leukemia reveals cardiac adaptation
by: Alia Sadiq, et al.
Published: (2025-06-01)

Deep Dive into Targeted Therapies: Understanding IDH1-Mutant AML Treatments [Podcast]
by: Zeidan AM, et al.
Published: (2025-07-01)

NF1 expression profiling in IDH-wildtype glioblastoma: genomic associations and survival outcomes
by: Michael Chang, et al.
Published: (2024-10-01)

IDH status dictates oHSV mediated metabolic reprogramming affecting anti-tumor immunity
by: Upasana Sahu, et al.
Published: (2025-04-01)

A new IDH-independent hypermethylation phenotype is associated with astrocyte-like cell state in glioblastoma
by: Ana Luisa Costa, et al.
Published: (2025-07-01)

Predicting p53 Status in IDH‐Mutant Gliomas Using MRI‐Based Radiomic Model
by: Jiamin Li, et al.
Published: (2025-08-01)

SKP2 ubiquitylation modifies IDH1 to regulate hepatoblastoma cell cycle and glucose metabolism
by: Pengxiang Yu, et al.
Published: (2025-08-01)

A dual-genotype IDH-mutant infiltrating glioma, a real oligoastrocytoma in cerebral hemisphere
by: Jing Liu, PhD, et al.
Published: (2025-06-01)

De novo design of mIDH1 inhibitors by integrating deep learning and molecular modeling
by: Dingkang Sun, et al.
Published: (2024-10-01)

Concurrent PIK3CA and IDH1 variants in facial infiltrating lipomatosis with intracranial lesions
by: Hongrui Chen, et al.
Published: (2025-03-01)

Gemistocytic tumor cells programmed for glial scarring characterize T cell confinement in IDH-mutant astrocytoma
by: Levi van Hijfte, et al.
Published: (2025-01-01)

ATRX, OLIG2, MGMT, and IDH2 in Glioblastoma: Essential Molecular Mechanisms and Therapeutic Significance
by: Andrea Pop-Crisan, et al.
Published: (2025-04-01)

Prognostic impact of co-mutations in adults with IDH1/2-mutated acute myeloid leukemia
by: Anli Lai, et al.
Published: (2025-06-01)

Response and outcomes of patients with IDH1/2- mutated accelerated/blast-phase myeloproliferative neoplasms
by: Leah A. Goldberg, et al.
Published: (2025-05-01)

An eXplainable deep learning model for multi-modal MRI grading of IDH-mutant astrocytomas
by: Hamail Ayaz, et al.
Published: (2024-12-01)

Mutations in the “hot spots” of the <i>FLT3</i>, <i>NPM1</i>, <i>IDH1</i>, <i>IDH2</i> and <i>DNMT3A</i> genes in acute myeloid leukemia
by: E. N. Voropaeva, et al.
Published: (2025-03-01)

Predicting IDH and 1p/19q molecular status of gliomas with multi-b values DWI
by: Shanshan Zhao, et al.
Published: (2025-07-01)

Functional cure with single agent olutasidenib in relapsed IDH1/NPM1 co-mutated AML
by: Justin Watts, et al.
Published: (2025-07-01)

An Analysis for IDH‐Mutant Grade 4 Astrocytoma Based on WHO CNS 5: Implication of Clinical Practice
by: Xianxin Qiu, et al.
Published: (2025-07-01)